Cargando…
Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma
BACKGROUND: Angiogenesis is essential for tumour growth and metastasis. There are conflicting reports as to whether microvessel density (MVD) using the endothelial marker CD105 (cluster of differentiation molecule 105) in clear-cell renal cell carcinomas (ccRCC) is associated with prognosis. Recentl...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3974088/ https://www.ncbi.nlm.nih.gov/pubmed/24594997 http://dx.doi.org/10.1038/bjc.2014.71 |
_version_ | 1782479429293834240 |
---|---|
author | Saroufim, A Messai, Y Hasmim, M Rioux, N Iacovelli, R Verhoest, G Bensalah, K Patard, J-J Albiges, L Azzarone, B Escudier, B Chouaib, S |
author_facet | Saroufim, A Messai, Y Hasmim, M Rioux, N Iacovelli, R Verhoest, G Bensalah, K Patard, J-J Albiges, L Azzarone, B Escudier, B Chouaib, S |
author_sort | Saroufim, A |
collection | PubMed |
description | BACKGROUND: Angiogenesis is essential for tumour growth and metastasis. There are conflicting reports as to whether microvessel density (MVD) using the endothelial marker CD105 (cluster of differentiation molecule 105) in clear-cell renal cell carcinomas (ccRCC) is associated with prognosis. Recently, CD105 has been described as a RCC cancer stem cell marker. METHODS: A total of 102 ccRCC were analysed. Representative tumour sections were stained for CD105. Vascularity (endothelial CD105) was quantified by MVD. The immunohistochemistry analysis detected positive (if present) or negative (if absent) CD105 tumoral staining. This retrospective population-based study was evaluated using Kaplan–Meier method, t-test and Cox proportional hazard model. RESULTS: We found that the expression of endothelial CD105 (MVD) negatively correlated with nuclear grade (P<0.001), tumour stage (P<0.001) and Leibovitch score (P<0.001), whereas the expression of tumoral CD105 positively correlated with these three clinicopathological factors (P<0.001). In multivariate analysis, tumoral CD105 was found to be an independent predictor of poor overall survival (P=0.002). CONCLUSIONS: We have shown for the first time that tumoral CD105 is an independent predictive marker for death risk and unfavourable prognosis in patients with ccRCC after curative resection. |
format | Online Article Text |
id | pubmed-3974088 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-39740882015-04-01 Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma Saroufim, A Messai, Y Hasmim, M Rioux, N Iacovelli, R Verhoest, G Bensalah, K Patard, J-J Albiges, L Azzarone, B Escudier, B Chouaib, S Br J Cancer Molecular Diagnostics BACKGROUND: Angiogenesis is essential for tumour growth and metastasis. There are conflicting reports as to whether microvessel density (MVD) using the endothelial marker CD105 (cluster of differentiation molecule 105) in clear-cell renal cell carcinomas (ccRCC) is associated with prognosis. Recently, CD105 has been described as a RCC cancer stem cell marker. METHODS: A total of 102 ccRCC were analysed. Representative tumour sections were stained for CD105. Vascularity (endothelial CD105) was quantified by MVD. The immunohistochemistry analysis detected positive (if present) or negative (if absent) CD105 tumoral staining. This retrospective population-based study was evaluated using Kaplan–Meier method, t-test and Cox proportional hazard model. RESULTS: We found that the expression of endothelial CD105 (MVD) negatively correlated with nuclear grade (P<0.001), tumour stage (P<0.001) and Leibovitch score (P<0.001), whereas the expression of tumoral CD105 positively correlated with these three clinicopathological factors (P<0.001). In multivariate analysis, tumoral CD105 was found to be an independent predictor of poor overall survival (P=0.002). CONCLUSIONS: We have shown for the first time that tumoral CD105 is an independent predictive marker for death risk and unfavourable prognosis in patients with ccRCC after curative resection. Nature Publishing Group 2014-04-01 2014-03-04 /pmc/articles/PMC3974088/ /pubmed/24594997 http://dx.doi.org/10.1038/bjc.2014.71 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Molecular Diagnostics Saroufim, A Messai, Y Hasmim, M Rioux, N Iacovelli, R Verhoest, G Bensalah, K Patard, J-J Albiges, L Azzarone, B Escudier, B Chouaib, S Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma |
title | Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma |
title_full | Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma |
title_fullStr | Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma |
title_full_unstemmed | Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma |
title_short | Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma |
title_sort | tumoral cd105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3974088/ https://www.ncbi.nlm.nih.gov/pubmed/24594997 http://dx.doi.org/10.1038/bjc.2014.71 |
work_keys_str_mv | AT saroufima tumoralcd105isanovelindependentprognosticmarkerforprognosisinclearcellrenalcellcarcinoma AT messaiy tumoralcd105isanovelindependentprognosticmarkerforprognosisinclearcellrenalcellcarcinoma AT hasmimm tumoralcd105isanovelindependentprognosticmarkerforprognosisinclearcellrenalcellcarcinoma AT riouxn tumoralcd105isanovelindependentprognosticmarkerforprognosisinclearcellrenalcellcarcinoma AT iacovellir tumoralcd105isanovelindependentprognosticmarkerforprognosisinclearcellrenalcellcarcinoma AT verhoestg tumoralcd105isanovelindependentprognosticmarkerforprognosisinclearcellrenalcellcarcinoma AT bensalahk tumoralcd105isanovelindependentprognosticmarkerforprognosisinclearcellrenalcellcarcinoma AT patardjj tumoralcd105isanovelindependentprognosticmarkerforprognosisinclearcellrenalcellcarcinoma AT albigesl tumoralcd105isanovelindependentprognosticmarkerforprognosisinclearcellrenalcellcarcinoma AT azzaroneb tumoralcd105isanovelindependentprognosticmarkerforprognosisinclearcellrenalcellcarcinoma AT escudierb tumoralcd105isanovelindependentprognosticmarkerforprognosisinclearcellrenalcellcarcinoma AT chouaibs tumoralcd105isanovelindependentprognosticmarkerforprognosisinclearcellrenalcellcarcinoma |